会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Preparation of novel particles for inhalation
    • 用于吸入的新型颗粒的制备
    • US06652837B1
    • 2003-11-25
    • US09394233
    • 1999-09-13
    • David A. EdwardsRobert S. LangerRita VanbeverJeffrey MintzesJue WangDonghao Chen
    • David A. EdwardsRobert S. LangerRita VanbeverJeffrey MintzesJue WangDonghao Chen
    • A61K912
    • A61K9/0075A61K9/1617A61K9/1623A61K9/1641A61K9/1647A61K9/1658A61K31/135A61K31/137A61K38/28A61K38/38A61K47/6927Y10S514/958
    • Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or negatively charged therapeutic agent and a charged molecule of opposite charge for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the particles are made of a biodegradable material and have a tap density less than 0.4 g/cm3 and a mass mean diameter between 5 &mgr;m and 30 &mgr;m, which together yield an aerodynamic diameter of the particles of between approximately one and three microns. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of poly(lactic acid) or poly(glycolic acid) or copolymers thereof. Alternatively, the particles may be formed solely of a therapeutic or diagnostic agent and a surfactant. Surfactants can be incorporated on the particle surface for example by coating the particle after particle formation, or by incorporating the surfactant in the material forming the particle prior to formation of the particle. Exemplary surfactants include phosphoglycerides such as dipalmitoyl phosphatidylcholine (DPPC). The particles can be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide a variety of therapeutic agents. Formation of complexes of positively or negatively charged therapeutic agents with molecules of opposite charge can allow control of the release rate of the agents into the blood stream following administration.
    • 提供了将具有正或负电荷的治疗剂的表面活性剂和/或亲水或疏水配合物和用于药物递送至肺系统的带电分子的相反电荷的颗粒,以及用于其合成和给药的方法。 在一个优选的实施方案中,颗粒由可生物降解的材料制成,并且具有小于0.4g / cm 3的振实密度和5μm和30μm之间的质量平均直径,这两个颗粒之间的颗粒的空气动力学直径在 大约一到三微米。 颗粒可以由可生物降解的材料如可生物降解的聚合物形成。 例如,颗粒可以由聚(乳酸)或聚(乙醇酸)或其共聚物形成。 或者,颗粒可以仅由治疗剂或诊断剂和表面活性剂形成。 表面活性剂可以结合在颗粒表面上,例如通过在颗粒形成之后涂覆颗粒,或者通过在形成颗粒之前将表面活性剂并入形成颗粒的材料中。 示例性表面活性剂包括磷酸甘油酯,例如二棕榈酰磷脂酰胆碱(DPPC)。 这些颗粒可以有效地雾化,用于给呼吸道施用以允许全身或局部递送各种各样的治疗剂。 正电荷或带负电荷的治疗剂与相反电荷分子的复合物的形成可以允许在给药后将药剂释放到血流中的释放速率。
    • 5. 发明授权
    • Preparation of particles for inhalation
    • 吸入颗粒的制备
    • US5985309A
    • 1999-11-16
    • US971791
    • 1997-11-17
    • David A. EdwardsRobert S. LangerRita VanbeverJeffrey MintzesJue WangDonghao Chen
    • David A. EdwardsRobert S. LangerRita VanbeverJeffrey MintzesJue WangDonghao Chen
    • A61K9/16A61K31/135A61K31/137A61K38/28A61K38/38A61K13/00
    • A61K9/1647A61K31/135A61K31/137A61K38/28A61K38/38
    • Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or negatively charged therapeutic agent and a charged molecule of opposite charge for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the particles are made of a biodegradable material and have a tap density less than 0.4 g/cm.sup.3 and a mass mean diameter between 5 .mu.m and 30 .mu.m, which together yield an aerodynamic diameter of the particles of between approximately one and three microns. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of poly(lactic acid) or poly(glycolic acid) or copolymers thereof. Alternatively, the particles may be formed solely of a therapeutic or diagnostic agent and a surfactant. Surfactants can be incorporated on the particle surface for example by coating the particle after particle formation, or by incorporating the surfactant in the material forming the particle prior to formation of the particle. Exemplary surfactants include phosphoglycerides such as dipalmitoyl phosphatidylcholine (DPPC). The particles can be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide a variety of therapeutic agents. Formation of complexes of positively or negatively charged therapeutic agents with molecules of opposite charge can allow control of the release rate of the agents into the blood stream following administration.
    • 提供了将具有正或负电荷的治疗剂的表面活性剂和/或亲水或疏水配合物和用于药物递送至肺系统的带电分子的相反电荷的颗粒,以及用于其合成和给药的方法。 在优选的实施方案中,颗粒由可生物降解的材料制成,并且具有小于0.4g / cm 3的振实密度和5μm至30μm之间的质量平均直径,其一起产生颗粒的空气动力学直径在约 一和三微米。 颗粒可以由可生物降解的材料如可生物降解的聚合物形成。 例如,颗粒可以由聚(乳酸)或聚(乙醇酸)或其共聚物形成。 或者,颗粒可以仅由治疗剂或诊断剂和表面活性剂形成。 表面活性剂可以结合在颗粒表面上,例如通过在颗粒形成之后涂覆颗粒,或者通过在形成颗粒之前将表面活性剂并入形成颗粒的材料中。 示例性表面活性剂包括磷酸甘油酯,例如二棕榈酰磷脂酰胆碱(DPPC)。 这些颗粒可以有效地雾化,用于给呼吸道施用以允许全身或局部递送各种各样的治疗剂。 正电荷或带负电荷的治疗剂与相反电荷分子的复合物的形成可以允许在给药后将药剂释放到血流中的释放速率。